90 related articles for article (PubMed ID: 21371774)
1. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Butts CA; Ding K; Seymour L; Twumasi-Ankrah P; Graham B; Gandara D; Johnson DH; Kesler KA; Green M; Vincent M; Cormier Y; Goss G; Findlay B; Johnston M; Tsao MS; Shepherd FA
J Clin Oncol; 2010 Jan; 28(1):29-34. PubMed ID: 19933915
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol.
Yamamoto N; Kenmotsu H; Yamanaka T; Nakamura S; Tsuboi M
Clin Lung Cancer; 2018 Jan; 19(1):e1-e3. PubMed ID: 28668204
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
5. Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial.
Toubat O; Ding L; Ding K; Wightman SC; Atay SM; Harano T; Kim AW; David EA
Semin Thorac Cardiovasc Surg; 2024 Summer; 36(2):261-270. PubMed ID: 36272526
[TBL] [Abstract][Full Text] [Related]
6. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.
Lin ZZ; Shau WY; Shao YY; Yang YY; Kuo RN; Yang JC; Lai MS
Oncologist; 2012; 17(10):1294-302. PubMed ID: 22826374
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
Matsubara T; Yamaguchi M; Shimokawa M; Okamoto I
Clin Lung Cancer; 2024 May; 25(3):280-283. PubMed ID: 38368174
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the efficacy of postoperative adjuvant chemotherapy for stage IB non-small cell lung cancer.
Liu S; Wan S; Feng J; Pang Y; Wang H; Zeng H; Xu X
Medicine (Baltimore); 2024 Jan; 103(1):e36839. PubMed ID: 38181235
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.
Garon EB; Lu S; Goto Y; De Marchi P; Paz-Ares L; Spigel DR; Thomas M; Yang JC; Ardizzoni A; Barlesi F; Orlov S; Yoshioka H; Mountzios G; Khanna S; Bossen C; Carbini M; Turri S; Myers A; Cho BC
J Clin Oncol; 2024 Jan; 42(2):180-191. PubMed ID: 37788412
[TBL] [Abstract][Full Text] [Related]
10. A Nomogram to Predict the Overall Survival of Patients With Resected T1-2N0-1M0 Non-Small Cell Lung Cancer and to Identify the Optimal Candidates for Adjuvant Chemotherapy in Stage IB or IIA Non-Small Cell Lung Cancer Patients.
Wang W; Zhou J
Cancer Control; 2023; 30():10732748231197973. PubMed ID: 37703536
[TBL] [Abstract][Full Text] [Related]
11. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X; Rousseau V; Sun H; Lantuejoul S; Filipits M; Pirker R; Popper H; Mendiboure J; Vataire AL; Le Chevalier T; Soria JC; Brambilla E; Dunant A; Hainaut P;
Mol Oncol; 2014 May; 8(3):555-64. PubMed ID: 24495481
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis.
Noritake O; Nakamura S; Kinoshita F; Aokage K; Asao T; Matsuura Y; Chen-Yoshikawa TF
Lung Cancer; 2024 Feb; 188():107470. PubMed ID: 38237212
[TBL] [Abstract][Full Text] [Related]
13. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.
Miksad RA; Gönen M; Lynch TJ; Roberts TG
J Clin Oncol; 2009 May; 27(13):2245-52. PubMed ID: 19307513
[TBL] [Abstract][Full Text] [Related]
14. The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.
Leiter A; Kong CY; Gould MK; Kale MS; Veluswamy RR; Smith CB; Mhango G; Huang BZ; Wisnivesky JP; Sigel K
PLoS One; 2022; 17(11):e0263911. PubMed ID: 36378625
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer.
Cheng YF; Chen YL; Liu CC; Lin CM; Tong SS; Wang BY
Sci Rep; 2023 Nov; 13(1):19137. PubMed ID: 37932436
[TBL] [Abstract][Full Text] [Related]
16. Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail?
Russell PA; Wright GM
Ann Transl Med; 2016 Jan; 4(1):16. PubMed ID: 26855952
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy after complete resection of non-small cell lung cancer.
Laack E; Bokemeyer C; Hossfeld DK
Dtsch Arztebl Int; 2008 Apr; 105(14):249-54. PubMed ID: 19629205
[TBL] [Abstract][Full Text] [Related]
18. For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104).
Suda K
Transl Lung Cancer Res; 2019 Dec; 8(Suppl 4):S395-S399. PubMed ID: 32038923
[No Abstract] [Full Text] [Related]
19. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Salazar MC; Rosen JE; Wang Z; Arnold BN; Thomas DC; Herbst RS; Kim AW; Detterbeck FC; Blasberg JD; Boffa DJ
JAMA Oncol; 2017 May; 3(5):610-619. PubMed ID: 28056112
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split-dose administration of cisplatin after complete resection of stage II-IIIA non-small cell lung cancer.
Funaguchi N; Iihara H; Kaito D; Gomyo T; Sasaki Y; Yanase K; Endo J; Ito F; Hirose C; Ohno Y; Okura H
Mol Clin Oncol; 2022 Apr; 16(4):76. PubMed ID: 35251627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
